YMB YM Bio.'b'ser1

    YM BioSciences Annual Meeting of Shareholders and live audio webcast

 

    MISSISSAUGA, ON, Dec. 1 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), the cancer drug development company with an advanced-stage

portfolio, will hold its Annual and Special Meeting of Shareholders on

Wednesday, December 8th, 2004 at 4:30pm at Heenan Blaikie, Royal Bank Plaza,

200 Bay Street, Suite 2600, Toronto, Ontario.

    Mr. David G.P. Allan, YM's Chairman and CEO, will review the important

events of the past year and present the Company's outlook for 2005 and beyond.

 

    What:     Annual and Special Meeting of Shareholders of YM BioSciences

              Inc.

 

    Where:    Heenan Blaikie, Royal Bank Plaza, 200 Bay Street, Suite 2600,

              Toronto, Ontario.

 

    When:     Wednesday, December 8th, 2004 at 4:30pm

 

    Webcast:  YM BioSciences's Annual and Special Meeting will be Webcast in

              real time. The Webcast can be viewed online starting at 4:30pm

              at www.ymbiosciences.com or www.financialdisclosure.ca. The

              Webcast will be archived for 12 months.

 

    About YM BioSciences

 

    YM BioSciences Inc. is a cancer drug development company. Its lead drug,

tesmilifene, is a small molecule chemopotentiator (for taxanes and

anthracyclines) currently undergoing a pivotal Phase III trial in metastatic

breast cancer. Tesmilifene has completed a previous Phase III trial with

positive results. In addition to tesmilifene, the Company is developing an

EGFr humanized monoclonal antibody that is being tested in glioma and

pancreatic cancer in Phase II trials, has completed Phase II trials in head &

neck cancer, and is expected to enter a Phase III trial in 2005. A GnRH anti-

cancer vaccine is in earlier stage clinical trials.

 

    Except for historical information, this press release may contain forward-

looking statements, which reflect the Company's current expectation regarding

future events. These forward-looking statements involve risk and

uncertainties, which may cause but are not limited to, changing market

conditions, the successful and timely completion of clinical studies, the

establishment of corporate alliances, the impact of competitive products and

pricing, new product development, uncertainties related to the regulatory

approval process and other risks detailed from time to time in the Company's

ongoing quarterly and annual reporting.

 

    For further information: Enquiries: James Smith, The Equicom Group Inc.,

Tel. (416) 815-0700 x 229, Email: jsmith(at)equicomgroup.com; Carolyn McEwen,

YM BioSciences Inc., Tel. (905) 629-9761, Fax. (905) 629-4959, Email:

ir(at)ymbiosciences.com

    (YM. YMI YMBA)

 

    -30-

 

 

 

 

 

 

 

 

 

 

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jun 2024 to Jul 2024

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jul 2023 to Jul 2024